Recommendations for real‐world evidence of efficacy and safety of <scp>GLP</scp> ‐1 agonists in Prader‐Willi syndrome: Report of a workshop held by the Foundation for Prader‐Willi Research and International Prader Willi Syndrome Organisation

Nick Finer: Unremunerated president and trustee of IPWSO. Theresa Strong: Consultant for Soleno Therapeutics. Diane E. J. Stafford: Local PI for clinical trials sponsored by Aardvark Therapeutics, Acadia Pharmaceuticals and Ascendis Pharma. Advisory Committee for Soleno Therapeutics. Caroline Vrana-Diaz declares no conflicts of interest. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70282. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.